

PRESS RELEASE

11 AUGUST 2026

NANOLOGICA AB APPONTS AXEL ELNER AS NEW CFO

Nanologica AB (publ) has appointed Axel Elner as new CFO. Axel Elner will take up the position on 10 November 2026.

Axel Elner joins Nanologica from Viaplay Group AB and the role as Vice President Integration where he has led the integration of Allente into Viaplay Group with responsibility for executing cost synergies, operational integration and commercial value creation. Prior to that, Axel held various roles within Allente Nordic AB, including Director Finance and M&A Nordics and Interim Group CFO, with responsibility for financial reporting, capital allocation and M&A, among other things.

"We are very pleased to welcome Axel to Nanologica. We are facing a commercial expansion of both of the Group's business areas and Axel will play an important role in this. His experience in financial management and reporting, strategic change management and driving integration processes with a focus on synergies will be valuable for the Group's continued development", comments Nanologica's CEO Andreas Bhagwani.

Axel Elner succeeds Eva Osterman, who has decided to leave Nanologica per 31 August 2026. The Board of Directors and management would like to extend a warm thank you to Eva Osterman for her significant contributions during her time in the company and wish her the best of luck in future assignments. During the transition period, the CFO's responsibilities will be managed within the company's existing management organization.

For further information, please contact:

Johanna Westerberg, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica's offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica's share (ticker NICA) has been listed on Nasdaq Stockholm's main market since 2022. For further information, please visit www.nanologica.com.